galectin-3

galectin-3

A 30-kD protein, a beta-galactosidase-binding lectin encoded by LGALS3 on chromosome 14q22.3, which is thought to be involved in cell growth, adhesion, acute inflammation (neutrophil activation and adhesion, chemoattraction of macrophages, and activation of mast cells), mRNA splicing and processing, and apoptosis.

Normal expression
Mainly in the nucleus of epithelial and immune cells, neutrophils, and vascular endothelium.

Abnormal expression
Over-expression is linked to malignant transformation and metastases in carcinomas of the breast, colon, tongue, liver, and thyroid.
References in periodicals archive ?
2, said the team has found the novel role of Galectin-3 (Gal3) in promoting microglia-mediated neuroinflammation -- which subsequently worsens neurodegenerative disorders like Huntington's disease and Alzheimer's.
In addition, we have been actively involved in the design of these upcoming trials and believe that this study could further the understanding of NASH and the role Galectin-3 inhibition may play in the treatment of this growing epidemic.'
Low levels of coronary artery calcification (CAC), low galectin-3 levels, and absence of carotid plaque were all linked to a lower likelihood of atherosclerotic disease than might be expected based on traditional risk assessment, according to the authors of analysis of a large, contemporary cohort of elderly individuals published in the Journal of the American College of Cardiology.
Galectin-3 is an endogenous carbohydrate-binding protein that has been shown to have a variety of cellular functions (16).
One such driver of aging is a protein called galectin-3. Galectin-3 contributes to ongoing inflammatory conditions.
Differential expression of galectin-1 and galectin-3 during first trimester human embryogenesis.
Galecto will use the proceeds to conduct a phase 2/3 clinical study of inhaled TD139, a potent and selective inhibitor of galectin-3, in idiopathic pulmonary fibrosis, a chronic and severe disease characterized by progressive decline in lung function.
The research, conducted by at Lund University in Sweden, suggests that galectin-3 levels may be useful for diagnosis of depression or may be a new target for treating depression associated with type-1 diabetes, which could lead to better patient care.
Galectin Therapeutics announced it is proceeding with plans for a Phase 3 clinical trial program with its galectin-3 inhibitor GR-MD-02 in NASH cirrhosis, incorporating advice and guidance obtained in a meeting with the FDA.
The novel cardiac biomarker galectin-3 (Gal-3) is a beta galactoside binding lectin involved in fibrogenesis and inflammatory response in the failing heart.